Iovance Biotherapeutics Inc
NASDAQ:IOVA
| Market Cap (Intraday) | 3.04B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $9.72 |
| 50-Day MA | $10.02 |
| 200-Day MA | $10.52 |
Iovance Biotherapeutics Inc Stock, NASDAQ:IOVA
825 Industrial Road, Suite 400, San Carlos, California 94070
United States of America
Phone: +1.650.260.7120
Number of Employees: 557
Description
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.